Diamyd Medical AB (publ)

SSE:DMYD-B.ST

13.3 (SEK) • At close February 20, 2024
Bedrijfsnaam Diamyd Medical AB (publ)
Symbool DMYD-B.ST
Munteenheid SEK
Prijs 13.3
Beurswaarde 1,226,345,120
Dividendpercentage 0%
52-weken bereik 6.41 - 20.992
Industrie Biotechnology
Sector Healthcare
CEO Mr. Ulf Hannelius MBA, Ph.D.
Website https://www.diamyd.com

An error occurred while fetching data.

Over Diamyd Medical AB (publ)

Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is

Vergelijkbare Aandelen

Cantargia AB (publ) logo

Cantargia AB (publ)

CANTA.ST

3.32 SEK

C-Rad AB (publ) logo

C-Rad AB (publ)

CRAD-B.ST

46.55 SEK

Senzime AB (publ) logo

Senzime AB (publ)

SEZI.ST

7.25 SEK

Xspray Pharma AB (publ) logo

Xspray Pharma AB (publ)

XSPRAY.ST

44 SEK

ADDvise Group AB (publ) logo

ADDvise Group AB (publ)

ADDV-A.ST

11.6 SEK

Isofol Medical AB (publ) logo

Isofol Medical AB (publ)

ISOFOL.ST

0.616 SEK

Biovica International AB (publ) logo

Biovica International AB (publ)

BIOVIC-B.ST

2.34 SEK

Paxman AB (publ) logo

Paxman AB (publ)

PAX.ST

38.6 SEK

Xbrane Biopharma AB (publ) logo

Xbrane Biopharma AB (publ)

XBRANE.ST

2.085 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)